Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 7/20 | 1.00 |
| ▸ | PPARD | Q03181 | 6/20 | 1.00 |
| ▸ | PPARA | Q07869 | 6/20 | 1.00 |
| ▸ | F7 | P08709 | 5/20 | 1.00 |
| ▸ | F3 | P13726 | 5/20 | 1.00 |
| ▸ | FFAR1 | O14842 | 3/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 3/20 | 1.00 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 1.00 |
| ▸ | ESR1 | P03372 | 1/20 | 1.00 |
| ▸ | SRD5A2 | P31213 | 1/20 | 1.00 |
| ▸ | CASP6 | P55212 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.96 |
| ▸ | FABP4 | P15090 | 4/20 | 0.96 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.96 |
| ▸ | LMNA | P02545 | 3/20 | 0.96 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.96 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.96 |
| ▸ | NR4A2 | P43354 | 3/20 | 0.96 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.96 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.96 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gamolenic Acid SCHEMBL6686740 | 1.00 | PPARG (1.00) | PPARGPPARDPPARAF7F3 | |
| Gamolenic Acid SCHEMBL6686744 | 1.00 | PPARG (1.00) | PPARGPPARDPPARAF7F3 | |
| SCHEMBL2852855 | 1.00 | PPARG (1.00) | PPARGPPARDPPARAF7F3 | |
| SCHEMBL2852857 | 1.00 | PPARG (1.00) | PPARGPPARDPPARAF7F3 | |
| Gamolenic Acid SCHEMBL154896 | 1.00 | PPARG (1.00) | PPARGPPARDPPARAF7F3 | |
| SCHEMBL15902383 | 1.00 | PPARG (1.00) | PPARGPPARDPPARAF7F3 | |
| SCHEMBL25316078 | 1.00 | PPARG (1.00) | PPARGPPARDPPARAF7F3 | |
| SCHEMBL15610707 | 1.00 | PPARG (1.00) | PPARGPPARDPPARAF7F3 | |
| SCHEMBL7552065 | 1.00 | PPARG (1.00) | PPARGPPARDPPARAF7F3 | |
| Gamolenic Acid SCHEMBL16637145 | 1.00 | PPARG (1.00) | PPARGPPARDPPARAF7F3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 198 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106998743-B | Compounds for modulating fatty acid receptor activity and pet food comprising the same | 马斯公司 | 2024-05-24 | — | — | CN | claimed |
| CN-116194768-A | Application of ultra-fast gas-phase electronic nose in fatty acid detection | 佳禾食品工业股份有限公司 | 2023-05-30 | — | — | CN | claimed |
| CN-113773654-A | Antibacterial material and preparation method thereof | 河南迪怡疗护科技开发有限公司 | 2021-12-10 | — | — | CN | claimed |
| CN-113583454-A | Antibacterial medical material and antibacterial medical instrument | 河南迪怡疗护科技开发有限公司 | 2021-11-02 | — | — | CN | claimed |
| CN-112996500-A | Compositions and methods for modulating ELOVL2 | 优美佳生物技术有限公司 | 2021-06-18 | — | — | CN | claimed |
| CN-110591492-A | Antistatic epoxy ester modified styrene-acrylic resin anticorrosive paint | 厦门珉瑶贸易有限公司 | 2019-12-20 | — | — | CN | claimed |
| US-20150209441-A1 | Anandamide-Modified Nucleic Acid Molecules | BASECLICK GMBH (DE) | 2015-07-30 | — | — | US | claimed |
| EP-2872180-A1 | ANANDAMIDE-MODIFIED NUCLEIC ACID MOLECULES | Baseclick GmbH (DE) | 2015-05-20 | — | — | EP | claimed |
| EP-2231173-B1 | NUTRACEUTICAL COMPOSITION AND METHODS OF USE | DACY TECH PTY LTD (AU) | 2014-05-14 | — | — | EP | claimed |
| WO-2014009429-A1 | ANANDAMIDE-MODIFIED NUCLEIC ACID MOLECULES | LUDWIG-MAXIMILIANS-UNIVERSITÄT MÜNCHEN (DE) | 2014-01-16 | — | — | WO | claimed |
| EP-2231173-A1 | NUTRACEUTICAL COMPOSITION AND METHODS OF USE | Dacy Tech Pty Ltd (AU) | 2010-09-29 | — | — | EP | claimed |
| WO-2009073930-A1 | NUTRACEUTICAL COMPOSITION AND METHODS OF USE | DACY TECH PTY LTD (AU) | 2009-06-18 | — | — | WO | claimed |
| US-6436416-B1 | — | — | None | — | — | US | disclosed |
| EP-3817810-B1 | MANUFACTURING PROCESS AND INTERMEDIATES FOR A PYRROLO[2,3- D]PYRIMIDINE COMPOUND AND USE THEREOF | PFIZER (US) | 2025-09-17 | — | — | EP | disclosed |
| US-20250282789-A1 | CRYSTALLINE PYRIMIDINYL-3,8-DIAZABICYCLO[3.2.1]OCTANYLMETHANONE COMPOUND AND USE THEREOF | PFIZER INC. (US) | 2025-09-11 | — | — | US | disclosed |
| US-12410172-B2 | Crystalline forms of 3-cyano-1-[4-[6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]-1H-pyrazol-1-yl]cyclobutaneacetonitrile, and use thereof | PFIZER INC. (US) | 2025-09-09 | — | — | US | disclosed |
| EP-0465546-A1 | MICROBIOLOGICAL PRODUCTION OF POLYESTERS. | UNIV GRONINGEN (NL) | 1992-01-15 | — | — | EP | disclosed |
| WO-1990012104-A1 | MICROBIOLOGICAL PRODUCTION OF POLYESTERS | RIJKSUNIVERSITEIT TE GRONINGEN (NL) | 1990-10-18 | — | — | WO | disclosed |
| US-4783408-A | Method for the preparation of a fungal body and a lipid rich in Y-linolenic acid therefrom | DIRECTOR-GENERAL OF THE AGENCY OF INDUSTRIAL SCIENCE & TECHNOLOGY (JP) | 1988-11-08 | — | — | US | disclosed |
| EP-0155420-B1 | A METHOD FOR THE PREPARATION OF A FUNGAL BODY AND A LIPID RICH IN GAMMA-LINOLENIC ACID THEREFROM | The Agency of Industrial Science and Technology (JP) | 1988-03-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250282789-A1 | CRYSTALLINE PYRIMIDINYL-3,8-DIAZABICYCLO[3.2.1]OCTANYLMETHANONE COMPOUND AND USE THEREOF | PDXK, OR10J3, CYP2J2 | PPARG 643/4885PPARD 207/4885PPARA 240/4885 |
| US-12410172-B2 | Crystalline forms of 3-cyano-1-[4-[6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]-1H-pyrazol-1-yl]cyclobutaneacetonitrile, and use thereof | CYP4B1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CALU | PPARG 1333/4885PPARD 831/4885PPARA 668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.